GENinCode Plc
One St Peters Square
Manchester M2 3DE
United Kingdom
https://www.genincode.com
版塊: Healthcare
行業: Diagnostics & Research
全職員工: 42
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Matthew Heaton Walls | Co-Founder, CEO & Director | 288.59k | 無 | 1964 |
| Mr. Jordi Puig Gilberte | Co-Founder, COO & Director | 140.01k | 無 | 1975 |
| Mr. Paul Andrew Peter Foulger | CFO, Company Secretary & Director | 138.83k | 無 | 1969 |
描述
GENinCode Plc develops and commercializes clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company's molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a patented genetic test to help user to adopt cardiovascular prevention steps; Lipid inCode, a genetic diagnostic test for familial hypercholesterolemia; SUDD inCode, a genetic test to diagnose the cause of sudden cardiac death and familial heart disease; Thrombo inCode, a genetic test for diagnosis of hereditary thrombophilia and the risk of thrombosis. In addition, the company offers Thrombo inCode Reproductive Health, a genetic test that offers information related to risk of thrombophilia and associated risks for future pregnancies. GENinCode Plc was incorporated in 2018 and is based in Manchester, the United Kingdom.
公司管治
截至 無 止，GENinCode Plc 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
